ESR1 and breast cancer: Studies have shown that luminal breast cancer generally has more favorable outcomes after RT compared to non-luminal breast cancer [8, 21, 28, 29], and distinct biological processes have been identified that impact prognosis and treatment response in estrogen receptor-positive (ER-positive) and estrogen receptor-negative (ER-negative) breast cancers [30].